Endocrine Fluidity

Authors

  • Sanjay Kalra Dept. of Endocrinology, Bharti Hospital, Karnal, Haryana, India; University Center for Research & Development, Chandigarh University, Mohali, Punjab, India
  • Nitin Kapoor Dept. of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India; Noncommunicable Disease Unit, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
  • Atul Dhingra Dept. of Endocrinology, Gangaram Bansal Hospital, Sri Ganganagar, Rajasthan, India

Keywords:

Gluconeogenesis, imeglimin, oxidative, phosphorylation, inhibitor, mitochondria, pharmacotherapeutics, type 2 diabetes mellitus

Abstract

Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Downloads

Published

2022-12-12

Issue

Vol. 33 No. 7 (2022)

Section

Guest Editorial

How to Cite

Endocrine Fluidity. (2022). Indian Journal Of Clinical Practice, 33(7), 8-9. https://ojs.ijcp.in/index.php/IJCP/article/view/208

Similar Articles

1-10 of 180

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 > >>